Who Supplies Fexofenadine to India from AUSTRALIA

To import finished pharmaceutical formulations containing Fexofenadine into India, the importing company must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The Central Drugs Standard Control Organisation (CDSCO) requires registration of the product, which involves submitting Form 40 or 41, depending on the product's classification. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificates, and stability data. The timeline for import drug registration can vary but typically ranges from 6 to 12 months. Fexofenadine formulations under HS Code 30049039 are subject to these requirements.

Imported Fexofenadine formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, and a Certificate of Analysis (CoA) is required for each batch. Stability data must comply with International Council for Harmonisation (ICH) guidelines, specifically for Zone IV conditions. The formulations must meet the standards set by the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.

Between 2024 and 2026, the CDSCO has updated import policies to streamline the registration process for pharmaceutical products, including Fexofenadine formulations. The introduction of the Production Linked Incentive (PLI) scheme has impacted the import of finished formulations by encouraging domestic manufacturing. Bilateral agreements between India and Australia have facilitated mutual recognition of Good Manufacturing Practices (GMP), simplifying the import process for Australian manufacturers.

India imports finished Fexofenadine formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as extended-release tablets, may not be produced locally. The market size for Fexofenadine formulations in India is substantial, with a growing consumer base seeking effective antihistamines for allergic conditions.

The Basic Customs Duty (BCD) for Fexofenadine formulations under HS Code 30049039 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is levied at 18%. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) imposes them. Exemption notifications can reduce the total landed duty percentage.

India sources Fexofenadine formulations from Australia due to the high quality and compliance with international standards. Australian manufacturers often hold patents for specific formulations and dosage forms, providing a competitive advantage. Other suppliers include China, Germany, and the United States, but Australia's share remains significant due to these factors.

India imports Fexofenadine formulations from Australia due to the availability of patented formulations and specialized dosage forms not produced domestically. Australian manufacturers offer high-quality products that meet international standards, ensuring efficacy and safety. The technological expertise and compliance with Good Manufacturing Practices (GMP) in Australia provide a competitive edge in the Indian market.

Compared to China, the European Union, and the United States, Australia offers Fexofenadine formulations with superior quality and compliance with international standards. While other countries may offer lower prices, Australia's products are often preferred for their reliability and adherence to Good Manufacturing Practices (GMP). This quality assurance justifies the higher cost and maintains a strong market presence in India.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal due to the reliability of Australian suppliers. However, it's prudent for importers to monitor these risks and develop contingency plans.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Payment (DA), or Documents Against Acceptance (DA), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities and compliance with Good Manufacturing Practices (GMP).

1. 1Obtain a Directorate General of Foreign Trade (DGFT) Importer Exporter Code (IEC).
2. 2Register the product with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form 40 or 41.
3. 3Provide a Certificate of Pharmaceutical Product (CoPP) from the manufacturer.
4. 4Ensure the manufacturer holds a valid Good Manufacturing Practice (GMP) certificate.
5. 5Submit stability data compliant with International Council for Harmonisation (ICH) guidelines.
6. 6Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, if required.
7. 7Engage a Customs House Agent (CHA) for customs clearance procedures.
8. 8Seek an advance ruling for HS Code 30049039 to confirm applicable duties and taxes.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) or Drug Master File Equivalent (DMF-E).
5. 5Stability data compliant with International Council for Harmonisation (ICH) guidelines, specifically for Zone IVa/IVb conditions.

6